Literature DB >> 15081540

Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors.

Amere Subbarao Sreedhar1, Gábor Nardai, Péter Csermely.   

Abstract

Molecular chaperones (heat shock proteins, Hsp-s) play a pleiotropic role in immunological functions. Hsp-s participate in the presentation of peptide antigens, folding of several immunologically important proteins, such as the MHC, and in the maintenance of the activation-competent conformation of key signaling molecules (mostly serine/threonine and tyrosine kinases) of B and T cells activation. The most abundant cytoplasmic chaperone, Hsp90, is in the center of these processes. In recent years Hsp90 inhibitors emerged as very promising anticancer agents. Not surprisingly, Hsp90 inhibitors behave as immunosuppressants, and also cause an induction of superoxide production. Here we extend our previous data by showing the enhancement of complement-induced lysis of several types of tumor cells after Hsp90 inhibition. This novel mechanism may significantly contribute to the anticancer effects of Hsp90 inhibitors in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15081540     DOI: 10.1016/j.imlet.2003.11.025

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  5 in total

Review 1.  Heat shock proteins as emerging therapeutic targets.

Authors:  Csaba Sõti; Enikõ Nagy; Zoltán Giricz; László Vígh; Péter Csermely; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Authors:  Jooeun Bae; Aditya Munshi; Cheng Li; Mehmet Samur; Rao Prabhala; Constantine Mitsiades; Kenneth C Anderson; Nikhil C Munshi
Journal:  J Immunol       Date:  2013-01-04       Impact factor: 5.422

3.  Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study.

Authors:  Abdullah Hacıhanefioglu; Emel Gonullu; Ozgur Mehtap; Hakan Keski; Melike Yavuz; Cengiz Ercin
Journal:  Med Oncol       Date:  2010-04-27       Impact factor: 3.064

Review 4.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

5.  Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.

Authors:  Perri Rozenberg; Lea Ziporen; Dana Gancz; Moran Saar-Ray; Zvi Fishelson
Journal:  Cell Death Dis       Date:  2018-02-02       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.